Skip to main content

Artesunate Side Effects

Medically reviewed by Last updated on May 17, 2022.

For the Consumer

Applies to artesunate: intravenous powder for injection


Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • jaundice (yellowing of the skin or eyes);

  • pale or yellowed skin, dark colored urine;

  • fever, confusion or weakness; or

  • kidney problems--swelling, urinating less, feeling tired or short of breath.

Common side effects may include:

  • kidney problems;

  • jaundice; or

  • abnormal urine tests.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to artesunate: intravenous powder for injection


Very common (10% or more): Anemia (sometimes severe; up to 65%), delayed hemolysis (up to 27%), thrombocytopenia (up to 18%), leukocytosis (up to 10%), posttherapy hemolytic anemia in travelers, mild and transient decrease in reticulocyte count

Common (1% to 10%): Lymphopenia, neutropenia (sometimes severe), disseminated intravascular coagulation, leukopenia, reduced reticulocyte count, posttherapy hemolytic anemia in endemic areas

Uncommon (0.1% to 1%): Agranulocytosis, reticulocytopenia, erythroblastopenia

Very rare (less than 0.01%): Pure red cell aplasia

Frequency not reported: Posttherapy hemolytic anemia (including cases requiring transfusion), immune-mediated hemolysis

Postmarketing reports: Delayed hemolysis, immune hemolytic anemia[Ref]


Very common (10% or more): Increased transaminase (up to 27%), hyperbilirubinemia (up to 14%)

Common (1% to 10%): Jaundice, transient elevation in liver transaminases (AST, ALT)

Uncommon (0.1% to 1%): Elevated liver enzymes

Rare (0.01% to 0.1%): Hepatitis, calculous cholecystitis[Ref]

Transient elevation in liver transaminases, nausea, vomiting, anorexia, and diarrhea have been reported commonly but it is unclear whether these events may have been symptoms of severe malaria.[Ref]


Very common (10% or more): Acute renal failure (up to 10%)

Common (1% to 10%): Acute renal failure requiring dialysis (included dialysis, hemodialysis, peritoneal dialysis), elevated creatinine[Ref]


Common (1% to 10%): Hemoglobinuria[Ref]


Common (1% to 10%): Acute respiratory distress syndrome, pneumonia, pulmonary edema, cough, nasal symptoms[Ref]


Common (1% to 10%): Diarrhea, abdominal pain/cramps, vomiting, nausea

Uncommon (0.1% to 1%): Mild gastrointestinal disturbances

Rare (0.01% to 0.1%): Elevated serum amylase, pancreatitis

Postmarketing reports: Pancreatitis[Ref]


Common (1% to 10%): Rash, alopecia

Frequency not reported: Stevens-Johnson syndrome, urticaria[Ref]

Nervous system

Common (1% to 10%): Significant neurologic impairments, dysgeusia, tinnitus (with or without decreased auditory function), dizziness, headache, lightheadedness, altered taste (metallic/bitter taste)

Very rare (less than 0.01%): Peripheral neuropathy, paresthesia

Frequency not reported: Loss of balance, hemiplegia/paresis, ataxia, tremor[Ref]


Common (1% to 10%): Insomnia

Frequency not reported: Neuropsychiatric symptoms, confusion, restlessness[Ref]


Common (1% to 10%): Pyrexia/fever, fatigue, malaise

Frequency not reported: Generalized weakness[Ref]


Common (1% to 10%): Anorexia[Ref]


Common (1% to 10%): Arthralgia, muscle disorders[Ref]


Common (1% to 10%): Pain at injection site[Ref]


Uncommon (0.1% to 1%): Rhythm disorders (bradycardia, sinus arrhythmia), conduction disorders (QTc lengthening, abnormal sinoatrial conduction)

Rare (0.01% to 0.1%): Arterial ischemia, hypertensive retinopathy

Frequency not reported: Cardiac arrest, atrioventricular block, possible QT prolongation[Ref]

At least 1 case of cardiac arrest has been reported in a patient with severe malaria with multiorgan failure; causality by this drug has not been established.[Ref]


Uncommon (0.1% to 1%): Hypersensitivity (allergic) reactions

Rare (0.01% to 0.1%): Severe allergic reaction (included urticarial rash, hypotension, pruritus, edema, dyspnea)

Postmarketing reports: Hypersensitivity, anaphylaxis[Ref]


1. World Health Organization "WHO Public Assessment Reports (WHOPARs)" (2020):

2. "Product Information. Artesunate (artesunate)." Amivas (2020):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.